^
Association details:
Biomarker:ARID1A mutation
Cancer:Endometrial Adenocarcinoma
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Excerpt:
...ARID1A alterations (>5% of prevalence in this cohort): non-small cell lung cancer, colorectal adenocarcinoma, breast cancer, melanoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma/hepatocellular carcinoma, gastric/esophageal adenocarcinoma, uterine/ovary endometrial (endometrioid) carcinoma (including clear-cell carcinoma), and urothelial bladder carcinoma....Median progression-free survival (PFS) after checkpoint blockade immunotherapy was significantly longer in the patients with ARID1A-altered tumors (n=46) than in those with ARID1A wild-type tumors (n=329) (11 months vs 4 months, p=0.006)….
DOI:
http://dx.doi.org/10.1136/jitc-2019-000438